The Technical Analyst
Omeros Corp [OMER]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Omeros Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
68.73% $4.64
Last updated: 3 jul 2022 - 20:04
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 310.31 mill |
| EPS: | 3.14 |
| P/E: | 1.478 |
| Earnings Date: | Aug 08, 2022 |
| SharesOutstanding: | 66.88 mill |
| Avg Daily Volume: | 1.335 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 1.478 | sector: PE 480.39 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| infx |
| Company: PE 1.478 | industry: PE 0.000 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$6.26 (34.85%) $1.617 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $0.456 ( +/- 9.83%) Range: 4.18 - 5.10 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-17 | Zumwalt Kurt | Buy | 7 500 | Stock Option (Right to Buy) |
| 2022-06-17 | Hanish Arnold C | Buy | 7 500 | Stock Option (Right to Buy) |
| 2022-06-17 | Hood Leroy E. Md Phd | Buy | 7 500 | Stock Option (Right to Buy) |
| 2022-06-17 | Demopulos Peter A Md | Buy | 7 500 | Stock Option (Right to Buy) |
| 2022-06-17 | Shah Rajiv | Buy | 7 500 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 41.39 |
| Last 100 transactions |
| Buy: 2 448 123 | Sell: 600 441 |
Forecast:
16:00 - $4.65
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.65
Forecast 2: 16:00 - $4.65
Forecast 3: 16:00 - $4.65
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.64 (68.73% ) |
| Volume | 13.36 mill |
| Avg. Vol. | 1.335 mill |
| % of Avg. Vol | 1 000.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OMER
8 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: -1.02 % | Avg return sell: 1.95 %
$1 invested is now $0.96 or -4.03% since 30-06-22
| Date | Signal | @ | Closed | % | Jun 30 - 14:25 | sell | $2.72 | $2.79 @ Jun 30 - 15:43 | 2.58% |
|---|---|---|---|---|
| Jun 30 - 13:41 | buy | $2.73 | $2.72 @ Jun 30 - 14:25 | -0.37% |
| Jun 30 - 13:10 | sell | $2.71 | $2.73 @ Jun 30 - 13:41 | 0.55% |
| Jun 30 - 12:39 | buy | $2.76 | $2.71 @ Jun 30 - 13:10 | -1.81% |
| Jun 30 - 11:10 | sell | $2.70 | $2.76 @ Jun 30 - 12:39 | 2.41% |
| Jun 30 - 10:30 | buy | $2.72 | $2.70 @ Jun 30 - 11:10 | -0.92% |
| Jun 30 - 09:29 | sell | $2.66 | $2.72 @ Jun 30 - 10:30 | 2.26% |
OMER
Latest Press Releases
2022-04-20 08:45:00 - Press Release
Omeros Announces Journal Of Clinical Oncology Publication Detailing Pivotal Trial Results For Narsoplimab In Hsct-tma
Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma), an often-lethal complication of stem-cell transplantation for which there is no approved treatment. the manuscript – narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibit
2022-01-19 17:52:00 - Press Release
Omeros Confirms Submission Of Response To Fda Regarding The Bla For Narsoplimab In The Treatment Of Hsct-tma
Seattle--(business wire)--omeros corporation (nasdaq: omer) today confirmed that earlier this month the company submitted to the u.s. food and drug administration (fda) its response to the agency's complete response letter (crl) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma). the response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory and legal experts that addr
2021-12-23 09:10:00 - Press Release
Omeros Completes Sale Of Omidria® Franchise To Rayner Surgical
Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that it has completed the sale of omidria (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to rayner surgical group inc., an affiliate of rayner surgical group limited. the transaction was completed pursuant to an asset purchase agreement that was announced on december 2, 2021. omeros received approximately $126 million in cash at closing. in addition, omeros retains and is entitled to collect the full amoun
2021-12-20 09:30:00 - Press Release
Omer Equity Alert: Rosen, A Top Ranked Law Firm, Encourages Omeros Corporation Investors With Losses To Inquire About Class Action Investigation - Omer
New york, dec. 20, 2021 /prnewswire/ -- why: new york, n.y., december 19, 2021.
2021-12-03 20:17:00 - Press Release
Ongoing Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Omeros Corporation And Encourages Investors With Losses To Contact The Firm
Los angeles, california--(newsfile corp. - december 3, 2021) - the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of omeros corporation ("omeros" or "the company") (nasdaq: omer) for violations of the securities laws.the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. omeros announced on october 1, 2021, that the fda found deficiencies with...
Latest News
2022-06-02 00:47:01 - Seeking Alpha
Omeros: On Death's Door
Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty.
2022-05-10 22:26:03 - Seeking Alpha
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Conference Call Participants Eric Joseph - JPMorgan Greg Harrison - Bank of America Brandon Folkes - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
2022-05-02 22:18:21 - Seeking Alpha
Omeros: The Weight Of The Wait, A Conundrum
Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting.
2022-03-01 20:01:08 - Seeking Alpha
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call Transcript
2022-02-28 09:59:43 - Zacks Investment Research
Why Earnings Season Could Be Great for Omeros (OMER)
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2022-02-21 07:49:50 - Seeking Alpha
Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting.
2022-01-20 06:54:20 - Benzinga
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory, and legal experts addressing the points raised by the FDA.
2021-12-15 13:06:21 - Zacks Investment Research
Do Options Traders Know Something About Omeros (OMER) Stock We Don't?
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
2021-12-06 08:12:17 - Seeking Alpha
Omeros: A New Year Beckons
Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00.
2021-12-02 15:01:35 - Pulse2
Omeros (OMER) Stock: Why The Price Jumped Today
The stock price of Omeros Corporation (NASDAQ: OMER) increased by over 7% during intraday trading. This is why it happened.